EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome

Eugene Yu-Hin Chan iD, Desmond Yat-Hin Yap, Manuela Colucci iD, Alison Lap-Tak Ma, Rulan S Parekh, Kjell Tullus

Clinical Journal of the American Society of Nephrology · 2023-04 · 18 (4) · 533-548

DOI: 10.2215/cjn.08570722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 22.02.2023. Verfasst von Eugene Yu-Hin Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Nephrology Centre, Hong Kong Children's Hospital, Kowloon, Hong Kong. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Agammaglobulinemia. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab is an established therapy in children with idiopathic nephrotic syndrome to sustain short- to medium-term disease remission and avoid steroid toxicities. Recent trials focus on its use as a first-line agent among those with milder disease severity. Rituximab is used in multidrug refractory nephrotic syndrome and post-transplant disease recurrence, although the evidence is much less substantial. Available data suggest that the treatment response to rituximab depends on various patient factors, dosing regimen, and the concomitant use of maintenance immunosuppression. After repeated treatments, patients are found to have an improving response overall with a longer relapse-free period. The drug effect, however, is not permanent, and 80% of patients eventually relapse and many will require an additional course of rituximab. This underpins the importance of understanding the long-term safety profile on repeated treatments. Although rituximab appears to be generally safe, there are concerns about long-term hypogammaglobulinemia, especially in young children. Reliable immunophenotyping and biomarkers are yet to be discovered to predict treatment success, risk of both rare and severe side effects, e.g. , persistent hypogammaglobulinemia, and guiding of redosing strategy. In this review, we highlight recent advances in the use of rituximab for childhood nephrotic syndrome and how the therapeutic landscape is evolving.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephrotic SyndromeAgammaglobulinemiaChildHumansChild, PreschoolRituximabGlucocorticoidsTreatment Outcome

Substanzen

RituximabGlucocorticoids

Autor:innen und Institutionen

  • Paediatric Nephrology Centre, Hong Kong Children's Hospital, Kowloon, Hong Kong.
  • Department of Paediatric and Adolescent Medicine, Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
  • Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
  • Renal Diseases Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Departments of Medicine and Pediatrics, Women's College Hospital, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.
  • Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

ORCID-Profile: Eugene Yu-Hin Chan, Manuela Colucci

Zitieren

APA

Chan, E. Y., Yap, D. Y., Colucci, M., Ma, A. L., Parekh, R. S., & Tullus, K. (2023). Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology, 18(4), 533-548. https://doi.org/10.2215/cjn.08570722

Vancouver

Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K. Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology. 2023;18(4):533-548. doi:10.2215/cjn.08570722

BibTeX
@article{Chan2023,
  author = {Chan, Eugene Yu-Hin and Yap, Desmond Yat-Hin and Colucci, Manuela and Ma, Alison Lap-Tak and Parekh, Rulan S and Tullus, Kjell},
  title = {Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2023},
  volume = {18},
  number = {4},
  pages = {533--548},
  doi = {10.2215/cjn.08570722}
}
Kostenlos starten →